Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kelly Mitchell

Nurse Practitioner, Adult Health Hackensack, NJ Nurse Practitioner

NPI 1174291058 CMS profile 10756943

92 2Nd St, Hackensack, NJ 07601

Open in the dashboard

General payments

$4,113

144 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Mitchell of Hackensack, NJ is reported in the CMS Open Payments database as having received $4,113 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,087 60
2024 General $2,383 55
2023 General $583 25
2022 General $59 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Mitchell
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Kelly Mitchell were reported at $1,087. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Kelly Mitchell Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $138 $43–$438 $132
2022 $59 $165 $54–$494 $149
2023 $583 $178 $61–$549 $160
2024 $2,383 $186 $62–$575 $164
2025 $1,087 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Blueprint Medicines Corporation $814 16 payments
  2. Novartis Pharmaceuticals Corporation $754 13 payments
  3. PharmaEssentia USA Corporation $354 10 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $290 10 payments
  5. Incyte Corporation $281 7 payments
  6. Taiho Oncology, Inc. $265 14 payments
  7. AbbVie, Inc. $204 6 payments
  8. Geron Corporation $164 10 payments
  9. Daiichi Sankyo Inc. $155 9 payments
  10. Astellas Pharma US Inc $95 5 payments
  11. Other $738 44 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,637 139 payments
  2. Honoraria $632 1 payment
  3. Consulting Fee $555 1 payment
  4. Education $289 3 payments
Products named General payments · program years 2022–2025
  1. Fabhalta $668 7 payments
  2. BESREMI $354 10 payments
  3. INQOVI $265 14 payments
  4. Lonsurf $265 14 payments
  5. ICLUSIG $191 9 payments
  6. VENCLEXTA $174 4 payments
  7. RYTELO $164 10 payments
  8. REBLOZYL $114 7 payments
  9. AYVAKIT $107 11 payments
  10. JAKAFI $92 5 payments
  11. Other $1,030 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

270

Median for Nurse Practitioner: 389

Drug cost

$1,256,663

Median for Nurse Practitioner: $21,885

Branded share of claims

26.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Onureg Azacitidine Brand 37 $815,869
Jakafi Ruxolitinib Phosphate Brand 23 $400,886
Venclexta Venetoclax Brand 11 $21,474
Posaconazole Generic 13 $11,667
Imatinib Mesylate Generic 18 $4,418
Ciprofloxacin Hcl Generic 33 $737
Potassium Chloride Generic 15 $326
Acyclovir Generic 20 $306
Hydroxyurea Generic 17 $275
Levofloxacin Generic 11 $181

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Fabhalta
  • Novartis Pharmaceuticals Corporation $596
$596 — —
BESREMI
  • PharmaEssentia USA Corporation $200
$200 — —
VENCLEXTA
  • AbbVie, Inc. $156
$156 11 —
AYVAKIT
  • Blueprint Medicines Corporation $93
$93 — —
Lonsurf
  • Taiho Oncology, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record